Lonza Group AG (LZAGY)
Chart Events
Performance Outlook
| Previous Close | 45.85 |
| Open | 46.97 |
| Bid | 0.00 x 0 |
| Ask | 0.00 x 0 |
| Day's Range | 46.12 - 46.99 |
| 52 Week Range | 45.47 - 66.00 |
| Volume | |
| Avg. Volume | 87,480 |
| Market Cap | 34.554B |
| Beta (5Y Monthly) | 0.57 |
| PE Ratio (TTM) | 27.99 |
| EPS (TTM) | 1.65 |
| Earnings Date | N/A |
| Forward Dividend & Yield | 0.39 (0.85%) |
| Ex-Dividend Date | May 09, 2023 |
| 1y Target Est | N/A |
Fair Value
Subscribe to Yahoo Finance Plus to view Fair Value for LZAGY
Related Research
- LONZA GROUP AG UNSP ADR EACH REAnalyst Report: Merck KGaAMerck KGaA operates in three main segments: life sciences, performance materials, and healthcare. The life sciences segment (47% of 2022 sales) primarily provides laboratory consumables and services to researchers in academia and applied fields, including the biopharmaceutical industry. In the healthcare segment (35%), Merck develops, manufactures, and sells branded pharmaceuticals with significant therapeutic concentrations in oncology, multiple sclerosis, and fertility. In its electronics segment (18%), the company offers specialty materials to manufacture a variety of products, such as semiconductors, flat-screen televisions, automobiles, and cosmetics. In 1995, the E. Merck KG family publicly sold part of the company, resulting in the current 30% public ownership of the firm.RatingFair ValueEconomic Moat4 days agoMorningstar
- Reuters
UPDATE 2-Moderna to cut mRNA drug substance production at Lonza facility
Moderna said on Tuesday it will cut production of mRNA drug substance for its COVID-19 vaccine at Lonza's facility in Switzerland this quarter as part of a plan to align manufacturing of the shots with lower post-pandemic demand. The U.S. company had said last week it was in talks with its partners that fill vials and syringes globally to downsize vaccine production. Such a move will help Moderna adjust to the sharp fall in demand for COVID vaccines as payers cut back orders for the shots, partly following the end of the public health emergency for the disease.
The Wall Street JournalLonza CEO Pierre-Alain Ruffieux to Leave
Lonza’s shares fell almost 7% on news the CEO would depart at the end of September, which RBC described as unexpected and was unlikely to provide the market with confidence heading into next month’s capital-markets day.
- Reuters
UPDATE 2-Swiss drug ingredient maker Lonza's CEO to leave
Contract drug manufacturer Lonza's Chief Executive, Pierre-Alain Ruffieux, will leave the Swiss company by mutual agreement at the end of the month, it said on Monday. Lonza said its medium-term strategy and outlook would be discussed in detail at its coming capital markets day on Oct. 17 and that Chairman Albert Baehny will take on the CEO responsibilities until the appointment of a permanent successor to Ruffieux. Shares in Lonza, which makes drug ingredients for healthcare and biotech companies, lost 3.3% in premarket trade.
